SLR14

SLR14 is a synthetic stem-loop RNA molecule designed as a potent and specific agonist of the cytosolic pattern recognition receptor RIG-I (Retinoic acid-inducible gene I). By mimicking viral RNA, SLR14 activates RIG-I signaling pathways, leading to robust induction of type I interferon (IFN-I) responses and downstream immune activation. Preclinical studies have demonstrated that intratumoral or systemic administration of SLR14 induces strong antitumor immunity in mouse models by enhancing infiltration and activation of CD8+ T cells, NK cells, and myeloid cells within the tumor microenvironment. In addition to its antitumor effects, SLR14 has shown broad-spectrum antiviral activity against SARS-CoV-2 in mice by preventing viral replication and disease progression through IFN-I–mediated innate immunity. The drug is being developed as both an immunotherapy for cancer—alone or in combination with checkpoint inhibitors—and as a host-directed antiviral agent for acute and chronic viral infections[1][2][4][5][6].

Other names

Stem Loop RNA 14stem-loop RNA 14